Jade Biosciences, Inc. (NASDAQ:JBIO) Given Average Recommendation of “Moderate Buy” by Analysts

Jade Biosciences, Inc. (NASDAQ:JBIO) has been assigned an average recommendation of “Moderate Buy” from the ten research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $47.1250.

Several analysts have weighed in on JBIO shares. UBS Group started coverage on Jade Biosciences in a research report on Monday, June 15th. They set a “buy” rating and a $45.00 price objective on the stock. HC Wainwright lifted their price objective on Jade Biosciences from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Jefferies Financial Group reaffirmed a “buy” rating on shares of Jade Biosciences in a research report on Monday, June 1st. Zacks Research raised Jade Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Finally, Stifel Nicolaus set a $40.00 price objective on Jade Biosciences in a research report on Friday, March 6th.

Institutional Trading of Jade Biosciences

Several large investors have recently bought and sold shares of JBIO. Legal & General Group Plc bought a new stake in Jade Biosciences during the 2nd quarter valued at approximately $29,000. Russell Investments Group Ltd. bought a new stake in Jade Biosciences during the 2nd quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new stake in Jade Biosciences during the 2nd quarter valued at approximately $32,000. California State Teachers Retirement System boosted its position in Jade Biosciences by 40.3% during the 4th quarter. California State Teachers Retirement System now owns 2,850 shares of the company’s stock valued at $44,000 after acquiring an additional 819 shares in the last quarter. Finally, Group One Trading LLC boosted its position in Jade Biosciences by 122.9% during the 4th quarter. Group One Trading LLC now owns 4,195 shares of the company’s stock valued at $65,000 after acquiring an additional 22,527 shares in the last quarter.

Jade Biosciences Price Performance

NASDAQ JBIO opened at $19.45 on Tuesday. The stock has a market capitalization of $960.05 million, a PE ratio of -9.63 and a beta of 1.45. Jade Biosciences has a 1 year low of $6.67 and a 1 year high of $28.00. The business’s 50-day moving average is $21.05 and its 200 day moving average is $17.00.

Jade Biosciences (NASDAQ:JBIO) last posted its earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.52) by ($0.05). As a group, equities research analysts anticipate that Jade Biosciences will post -2.54 earnings per share for the current year.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.